Wolfgang Miesbach/LinkedIn
Dec 7, 2025, 16:21
Wolfgang Miesbach: Beyond Immunosuppression – Two new ways to treat ITP
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
“Beyond Immunosuppression: Two new ways to treat ITP. David Kuter gave a great presentation at ASH 2025:
- Increase Platelet Production
The latest TPO receptor agonist, hetrombopag, now in Phase 3 trials, offers a direct pathway to boost platelet synthesis—moving away from suppression toward restoration. - Decrease Platelet Destruction
A diverse arsenal of targeted therapies can redefineour strategy:
– Anti-CD38 antibodies (daratumumab, mezagitamab)
– BAFF/BAFF-R inhibitors
– FcRn inhibitors (efgartigimod)
– BTK inhibitors (rilzabrutinib, orelabrutinib)
– Complement inhibitors + immunomodulatory approaches
– T-cell engagers and CAR-T therapies
ITP is now recognized as a disorder of both reduced production AND increased destruction—this understanding drives treatment selection toward complete remission, not just disease suppression.”

Find the full coverage of ASH25 in Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?